CymaBay Therapeutics shares jumped 24% early Monday after Gilead Sciences reached a $4.3 billion deal to acquire the liver-drug developer.
Source: MarketWatch
12. February 2024 15:35
CymaBay Therapeutics shares jumped 24% early Monday after Gilead Sciences reached a $4.3 billion deal to acquire the liver-drug developer.
Source: MarketWatch